{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T03:14:56Z","timestamp":1783307696721,"version":"3.54.6"},"reference-count":39,"publisher":"Journal of Biomedical Research","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Biomed Res"],"published-print":{"date-parts":[[2026]]},"DOI":"10.7555\/jbr.40.20260038","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:48:53Z","timestamp":1783147733000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["The single-cell atlas of programmed cell death signature: A machine learning-based prognostic framework in breast cancer"],"prefix":"10.7555","volume":"40","author":[{"given":"Jixuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuju","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4380","reference":[{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.1","doi-asserted-by":"publisher","unstructured":"Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040[J]. <i>Breast<\/i>, 2022, 66: 15\u201323.","DOI":"10.1016\/j.breast.2022.08.010"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.2","doi-asserted-by":"crossref","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025[J]. <i>CA Cancer J Clin<\/i>, 2025, 75(1): 10\u201345.","DOI":"10.3322\/caac.21871"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.3","doi-asserted-by":"crossref","unstructured":"Wang Z, Wang H. Acyl-CoA thioesterase 8 (ACOT8) is a poor prognostic biomarker in breast cancer[J]. <i>Pharmgenomics Pers Med<\/i>, 2024, 17: 403\u2013421.","DOI":"10.2147\/PGPM.S459762"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.4","doi-asserted-by":"publisher","unstructured":"Zhou Z, Bai N, Zheng W, et al. MultiOmics analysis of metabolic dysregulation and immune features in breast cancer[J]. <i>Int Immunopharmacol<\/i>, 2025, 152: 114376.","DOI":"10.1016\/j.intimp.2025.114376"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.5","doi-asserted-by":"publisher","unstructured":"Rayson VC, Harris MA, Savas P, et al. The anti-cancer immune response in breast cancer: Current and emerging biomarkers and treatments[J]. <i>Trends Cancer<\/i>, 2024, 10(6): 490\u2013506.","DOI":"10.1016\/j.trecan.2024.02.008"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.6","doi-asserted-by":"publisher","unstructured":"Xiong X, Zheng L, Ding Y, et al. Breast cancer: Pathogenesis and treatments[J]. <i>Signal Transduct Target Ther<\/i>, 2025, 10(1): 49.","DOI":"10.1038\/s41392-024-02108-4"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.7","doi-asserted-by":"publisher","unstructured":"Chen Y, Li X, Yang M, et al. Research progress on morphology and mechanism of programmed cell death[J]. <i>Cell Death Dis<\/i>, 2024, 15(5): 327.","DOI":"10.1038\/s41419-024-06712-8"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.8","doi-asserted-by":"publisher","unstructured":"Zhang X, Tao T, Qiu Y, et al. Copper-mediated novel cell death pathway in tumor cells and implications for innovative cancer therapies[J]. <i>Biomed Pharmacother<\/i>, 2023, 168: 115730.","DOI":"10.1016\/j.biopha.2023.115730"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.9","doi-asserted-by":"publisher","unstructured":"Din MAU, Lin Y, Wang N, et al. Ferroptosis and the ubiquitin-proteasome system: Exploring treatment targets in cancer[J]. <i>Front Pharmacol<\/i>, 2024, 15: 1383203.","DOI":"10.3389\/fphar.2024.1383203"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.10","doi-asserted-by":"crossref","unstructured":"Karati D, Kumar D. Molecular insight into the apoptotic mechanism of cancer cells: An explicative review[J]. <i>Curr Mol Pharmacol<\/i>, 2024, 17: e18761429273223.","DOI":"10.2174\/0118761429273223231124072223"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.11","doi-asserted-by":"crossref","unstructured":"Wang Y, Zhang Z, Sun W, et al. Ferroptosis in colorectal cancer: Potential mechanisms and effective therapeutic targets[J]. <i>Biomed Pharmacother<\/i>, 2022, 153(6): 113524.","DOI":"10.1016\/j.biopha.2022.113524"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.12","doi-asserted-by":"publisher","unstructured":"Wang S, Wang R, Hu D, et al. Machine learning reveals diverse cell death patterns in lung adenocarcinoma prognosis and therapy[J]. <i>npj Precis Oncol<\/i>, 2024, 8(1): 49.","DOI":"10.1038\/s41698-024-00538-5"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.13","doi-asserted-by":"publisher","unstructured":"Cao Q, Zhang JB, Sun DY, et al. Pyroptosis, metabolism, and oxidation in tumorigenesis: Mechanisms and therapeutic implications[J]. <i>Antioxid Redox Signal<\/i>, 2023, 39(7-9): 512\u2013530.","DOI":"10.1089\/ars.2023.0257"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.14","doi-asserted-by":"publisher","unstructured":"Low HB, Wong ZL, Wu B, et al. DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death[J]. <i>Nat Commun<\/i>, 2021, 12(1): 2284.","DOI":"10.1038\/s41467-021-22638-7"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.15","doi-asserted-by":"publisher","unstructured":"Koh M, Lim H, Jin H, et al. ANXA2 (annexin A2) is crucial to ATG7-mediated autophagy, leading to tumor aggressiveness in triple-negative breast cancer cells[J]. <i>Autophagy<\/i>, 2024, 20(3): 659\u2013674.","DOI":"10.1080\/15548627.2024.2305063"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.16","doi-asserted-by":"publisher","unstructured":"Xu X, Su Y, Shi J, et al. MicroRNA-17-5p promotes cardiac hypertrophy by targeting Mfn2 to inhibit autophagy[J]. <i>Cardiovasc Toxicol<\/i>, 2021, 21(9): 759\u2013771.","DOI":"10.1007\/s12012-021-09667-w"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.17","doi-asserted-by":"publisher","unstructured":"Niu X, You Q, Hou K, et al. Autophagy in cancer development, immune evasion, and drug resistance[J]. <i>Drug Resist Updat<\/i>, 2025, 78: 101170.","DOI":"10.1016\/j.drup.2024.101170"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.18","doi-asserted-by":"crossref","unstructured":"Zou Y, Xie J, Zheng S, et al. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery[J]. <i>Int J Surg<\/i>, 2022, 107: 106936.","DOI":"10.1016\/j.ijsu.2022.106936"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.19","doi-asserted-by":"publisher","unstructured":"Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. <i>Nucleic Acids Res<\/i>, 2020, 48(W1): W509\u2013W514.","DOI":"10.1093\/nar\/gkaa407"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.20","doi-asserted-by":"publisher","unstructured":"Racle J, de Jonge K, Baumgaertner P, et al. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data[J]. <i>eLife<\/i>, 2017, 6: e26476","DOI":"10.7554\/eLife.26476"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.21","doi-asserted-by":"publisher","unstructured":"Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression[J]. <i>Genome Biol<\/i>, 2016, 17(1): 218.","DOI":"10.1186\/s13059-016-1070-5"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.22","doi-asserted-by":"publisher","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data[J]. <i>Nat Commun<\/i>, 2013, 4: 2612.","DOI":"10.1038\/ncomms3612"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.23","doi-asserted-by":"crossref","unstructured":"Chen B, Khodadoust MS, Liu CL, et al. Profiling tumor infiltrating immune cells with CIBERSORT[M]\/\/von Stechow L. Cancer Systems Biology: Methods and Protocols. New York: Springer, 2018: 243\u2013259.","DOI":"10.1007\/978-1-4939-7493-1_12"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.24","doi-asserted-by":"publisher","unstructured":"Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response[J]. <i>Nat Med<\/i>, 2018, 24(10): 1550\u20131558.","DOI":"10.1038\/s41591-018-0136-1"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.25","doi-asserted-by":"crossref","unstructured":"Terry AR, Nogueira V, Rho H, et al. CD36 maintains lipid homeostasis via selective uptake of monounsaturated fatty acids during matrix detachment and tumor progression[J]. <i>Cell Metab<\/i>, 2023, 35(11): 2060\u20132076. e9.","DOI":"10.1016\/j.cmet.2023.09.012"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.26","doi-asserted-by":"publisher","unstructured":"Roda N, Cossa A, Hillje R, et al. A rare subset of primary tumor cells with concomitant hyperactivation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer[J]. <i>Cancer Res<\/i>, 2023, 83(13): 2155\u20132170.","DOI":"10.1158\/0008-5472.CAN-22-2717"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.27","doi-asserted-by":"publisher","unstructured":"Xu J, Shao C, Wang X, et al. circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p\/SOCS3 axis[J]. <i>Cell Death Dis<\/i>, 2019, 10(3): 175.","DOI":"10.1038\/s41419-019-1382-y"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.28","doi-asserted-by":"publisher","unstructured":"Thacker G, Henry S, Nandi A, et al. Immature natural killer cells promote progression of triple-negative breast cancer[J]. <i>Sci Transl Med<\/i>, 2023, 15(686): eabl4414.","DOI":"10.1126\/scitranslmed.abl4414"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.29","doi-asserted-by":"publisher","unstructured":"Wang Z, Moresco P, Yan R, et al. Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack[J]. <i>Proc Natl Acad Sci U S A<\/i>, 2022, 119(4): e2119463119.","DOI":"10.1073\/pnas.2119463119"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.30","doi-asserted-by":"publisher","unstructured":"Deng X, Zhang C, Xie J, et al. Disulfidptosis in cancer: From redox stress to therapeutic strategy[J]. <i>Cancer Gene Ther<\/i>, 2026, 33(1): 22\u201325.","DOI":"10.1038\/s41417-025-00985-7"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.31","doi-asserted-by":"crossref","unstructured":"Kather JN, Halama N, Jaeger D. Genomics and emerging biomarkers for immunotherapy of colorectal cancer[J]. <i>Semin Cancer Biol<\/i>, 2018, 52(Pt 2): 189\u2013197.","DOI":"10.1016\/j.semcancer.2018.02.010"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.32","doi-asserted-by":"publisher","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway[J]. <i>Nat Rev Immunol<\/i>, 2018, 18(3): 153\u2013167.","DOI":"10.1038\/nri.2017.108"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.33","doi-asserted-by":"publisher","unstructured":"Chen S, Deng X, He X, et al. Preventive effects of low-dose radiation and hypofractionated radiation plus anti-programmed cell death protein 1 on lung metastasis in breast cancer[J]. <i>Oncol Res<\/i>, 2025, 33(3): 687\u2013694.","DOI":"10.32604\/or.2024.052133"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.34","doi-asserted-by":"publisher","unstructured":"Tao J, Xue C, Cao M, et al. Protein disulfide isomerase family member 4 promotes triple-negative breast cancer tumorigenesis and radiotherapy resistance through JNK pathway[J]. <i>Breast Cancer Res<\/i>, 2024, 26(1): 1.","DOI":"10.1186\/s13058-023-01758-6"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.35","doi-asserted-by":"publisher","unstructured":"He X, Zhang H, Wang Y, et al. Plat safeguards maternally aged oocytes against programmed cell death through activating the Erk1\/2 pathway[J]. <i>Sci China Life Sci<\/i>, 2026, 69(2): 506\u2013522.","DOI":"10.1007\/s11427-025-3041-4"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.36","doi-asserted-by":"publisher","unstructured":"Shen Y, Zhang N, Chai J, et al. CircPDIA4 induces gastric cancer progression by promoting ERK1\/2 activation and enhancing biogenesis of oncogenic circRNAs[J]. <i>Cancer Res<\/i>, 2023, 83(4): 538\u2013552.","DOI":"10.1158\/0008-5472.CAN-22-1923"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.37","doi-asserted-by":"publisher","unstructured":"Xing F, Song Z, Cheng Z. High expression of PDIA4 promotes malignant cell behavior and predicts reduced survival in cervical cancer[J]. <i>Oncol Rep<\/i>, 2022, 48(4): 184.","DOI":"10.3892\/or.2022.8399"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.38","doi-asserted-by":"crossref","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer[J]. <i>npj Breast Cancer<\/i>, 2021, 7(1): 1.","DOI":"10.1038\/s41523-020-00208-2"},{"key":"10.7555\/JBR.40.20260038.swyxyjzzywb.39","doi-asserted-by":"publisher","unstructured":"Syed YY. Oncotype DX breast recurrence score<sup>\u00ae<\/sup>: a review of its use in early-stage breast cancer[J]. <i>Mol Diagn Ther<\/i>, 2020, 24(5): 621\u2013632.","DOI":"10.1007\/s40291-020-00482-7"}],"container-title":["Journal of Biomedical Research"],"original-title":[],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:30:13Z","timestamp":1783305013000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jbr-pub.org.cn\/article\/doi\/10.7555\/JBR.40.20260038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":39,"alternative-id":["JBR-2026-0038"],"URL":"https:\/\/doi.org\/10.7555\/jbr.40.20260038","relation":{},"ISSN":["1674-8301","1674-8301"],"issn-type":[{"value":"1674-8301","type":"print"},{"value":"1674-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}